Acei，referred to as Puli)、Calcium antagonist (CCB)、Vasopoeia tension Ⅱ receptor antagonist (ARB，Satan category) and & beta; blockers are the main varieties of the global hypertension drug therapy market。In the past five years，The wide use of a new generation of anti -hypertension drugs in China，greatly improved China's hypertension control rate，Objectively reducing the incidence of stroke。

 

  According to the newly released China's 10th "China Cardiovascular Disease Report"，In 2013, the direct economic burden of high blood pressure in China has increased to 210.65 billion yuan，6.61%of total health costs。With the youth trend of cardiovascular disease，Anti -hypertension is still a national strategic issue。

 

  With the increase in the number of hypertension people in my country，Facilities in national policies、Full coverage of the medical security system、Increasing the situation of science popularization of health stake online sports bettingstake online sports bettingknowledge，The people's medication level has increased year by year，Against the growth of anti -hypertension drug markets。According to the latest statistics，2015 China Anti -Hypertension Drug Market reached 25.239 billion yuan，increased by 12.52%year -on -year，Occupy 40%of the drugs of cardiovascular system。

 

  The growth rate is the first place

 

  Global clinical use of more ACEI (ACEI) category compound preparations are mainly diuretics (HCTZ)、Calcium antagonist (CCB) and folic acid composition。According to the Minenet HDM system data，In 2015, the amount of compound anti -hypertensive suppressive agent for the fixed dose of public hospitals in domestic key cities in China was 752 million yuan，increased by 16.70%year -on -year。The average annual growth rate of the five years of 2011-2015 reached 30.23%。2015，Driven by the academic promotion of new varieties，Complex Prubi drugs become a type of drug with high -speed growth。

 

 

  Data display，Public hospital hypertension therapy drugs，Fixed dosage compound Propyy drug growth rate ranks first，increased by 26%year -on -year，and the growth rate of compound Salin drugs decreased to 13.73%，Unilateral Salite and Prilum drugs are about 6%。

 

  Acei-Co (Acei-Co) drugs listed in the country are mainly ebulicinadaamamide、Irina Pripilic acid、Benapoli ammonia、Dhubi hydrochloride、Benapuli hydrochloride、Leninopoli hydrochloride、Seven varieties such as Katopoli hydrochlorozine。Foreign List is also listed in Dodinira Pami、Remy Prielfali equal variety。Although there are related research reports in China，But there is no listing variety，To develop in -depth。

 

 

  Pei Puli Dipaamine Leaders

 

  The first variety of sales in the compound Pully market is the Peter Plus Dippamam，It is the exclusive variety listed stake betting appby Shi stake betting appWeiya (Tianjin) Pharmaceutical Co., Ltd.，The product is named Baipule。Peiqi Plibaidamam is a type of low -dose compound preparation，Research and Development in 1993，Obtained CFDA approval in 2005，Listed in China in 2006。

 

  Best of Pule is composed of ACEI drugs Perlinine salt and diuretic antihypertensive drug，Anti -hypertension from different angles and different mechanisms，to play a synergy，Reduce adverse reactions of ACEI -like drugs to cause blood potassium to rise，Protecting the target organs，It is the primary hypertension first -line treatment of the Guide to Treatment of Hypertension in China。

 

  2011，Bai Pule started the real start in the hospital market，Then climb all the way。According to the HDM system data，In 2015, the amount of domestic public hospitals in public hospitals in Perlisa Dippamamine reached 32 million yuan，increased by 18.28%year -on -year。Conservative calculation，The domestic market size is about 200 million yuan。In recent years，In -depth development of ACEI compound drugs abroad，In January 2015, the FDA of the United States has approved SymplMed Pharmaceutical Company's Pei Procoline Piece Horizon Fixed Dose Compound Preparation Listing，Domestic drugs are still in preliminary research。

 

 

  Enna Pripiline tablets growth rate of 25.29%

 

  Enna Pronate F folk acid is the second place in ACEI-CO.。This drug is a new variety developed by Shenzhen Osa Pharmaceutical，It is used to treat primary hypertension that is accompanied by a higher level of plasma cysteine ​​(HCY).。

 

  2010，CFDA approves the listing of Yinna Prubiic acid tablets from Shenzhen Osa Pharmaceutical Co., Ltd.，The product is named & ldquo;。Malay sour Yinanini can reduce the blood pressure of patients with hypertension，Folic acid can reduce the level of plasma same cysteine，Give play to the role stake sports betting appof stake sports betting appsynergistic treatment，Treatment of hypertension while reducing the level of plasma same cysteine，It is a type of cardiovascular chemistry medicine with completely independent intellectual property rights in my country。Enna Pribiline tablets drive the rapid growth of the market with its unique mechanism。

 

  "Guidelines for Prevention and Control of Hypertension in China" pointed out，The increase in blood pressure in the Chinese population leads to 1.5 times the intensity of the stroke is 1.5 times in the Western population。Compared with the Western population，Plasma same cysteine ​​levels higher，Especially those with high HCY values ​​in the northerners are 2 to 4 times that of the southerners; while the HCY level of high blood pressure people is significantly higher than the normal crowd。Due to genetic genes、Environment and living habits and other reasons for many aspects，Plasma HCY level high、Low folic acid level，Adding micro -folic acid can help reduce the incidence of stroke。

 

  According to the HDM system data，In 2015, the amount of medicated tablet for public hospitals in the domestic key cities in China was 19 million yuan，increased by 25.29%year -on -year。Shenzhen Osa Pharmaceuticals by further strengthening academic promotion，Expand the brand awareness，further driving market development，It is expected that the sales of the product will reach a scale of more than 1 billion yuan in the next few years。

 

 

  It will become the main variety of high -end market

 

  Another five compound Pripi drugs are also a variety of rapid growth。According to the HDM system data，In 2015，Benapoli ammonia、Dhubi hydrochloride、Benapuli hydrochloride、Leninopoli hydrochloride、Catopoli hydrochlorozine growth rate reached 198.05%、50.45%、130%、26.47%and 20.02%。

 

  At present, domestic fixed dosage compound anti -hypertension drugs are in the starting stage，There are two reasons: First, the problem of cognitiveness，The other My stake betting appis stake sports betting appaffected by the bidding policy。Only some third -level hospitals have fixed dose compound preparations，and community hospitals are basically blank spots。With the entry of medical reforms & ldquo; Deepwater District & rdquo;，This situation will be changed。It is expected to be 2020，Anti -hypertension fixed dose compound preparation market will increase significantly，The potential market will get fast、Effective release，Industry experts think，Anti -hypertension fixed dose compound preparation will become the main variety of high -end markets。